Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Petru, E; Reinthaller, A; Angleitner-Boubenizek, L; Schauer, C; Zeimet, A; Dirschlmayer, W; Medl, M; Stummvoll, W; Sevelda, P; Marth, C.
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
WIEN KLIN WOCHENSCHR. 2010; 122(21-22): 649-652. Doi: 10.1007/s00508-010-1483-1
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz
Petru Edgar
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The Calypso trial showed an improved progression-free survival with PEG-liposomal doxorubicin (PLD) and carboplatin (P) as compared with the standard regimen paclitaxel (PCLTX) and P in the second- or third-line treatment of platinum-sensitive epithelial ovarian cancer [1]. A panel of Austrian gynecologic oncologists discussed the clinical consequences of the data from the Calypso study for the routine practice. PLD + P had a significantly lower rate of alopecia and neuropathy than the taxane regimen, both toxicities which compromise the quality of life. Due to possible significant thrombocytopenia, the blood counts of patients undergoing PLD + P therapy should be monitored weekly. Patients receiving PLD/P are at higher risk of nausea and vomiting. Palmoplantar erythrodysesthesia (hand-foot syndrome) is a significant toxicity of PLD + P most prevalent after the third or fourth cycle. Prophylaxis consists of avoiding pressure on feet and hands and other parts of the body. Similarly, prophylaxis of mucositis seems important and includes avoiding consumption of hot, spicy and salty foods and drinks. Mouth dryness should be avoided. Premedication with antiemetics and dexamethasone dissolved in 5% glucose is done to prevent hypersensitivity to PLD. In conclusion, the therapeutic index is more favorable for PLD + P than for PCTX + P.
Find related publications in this database (using NLM MeSH Indexing)
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - epidemiology
Carboplatin - therapeutic use
Doxorubicin - analogs and derivatives
Expert Testimony -
Female -
Humans -
Neoplasm Recurrence, Local - drug therapy
Ovarian Neoplasms - drug therapy
Paclitaxel - therapeutic use
Polyethylene Glycols - therapeutic use
Prevalence -
Randomized Controlled Trials as Topic -
Survival Analysis -
Survival Rate -
Treatment Outcome -

Find related publications in this database (Keywords)
Paclitaxel
carboplatin
pegylated liposomal doxorubicin
platinum-sensitive recurrence
ovarian cancer
neuropathy
alopecia
© Med Uni GrazImprint